Aerpio Pharmaceuticals, Inc. (NYSE:ARPO) Given Average Rating of “Buy” by Brokerages
Aerpio Pharmaceuticals, Inc. (NYSE:ARPO) has received an average broker rating score of 2.33 (Buy) from the three brokers that provide coverage for the stock, Zacks Investment Research reports. Two investment analysts have rated the stock with a hold recommendation and one has assigned a strong buy recommendation to the company. Aerpio Pharmaceuticals’ rating score has declined by 3.6% in the last 90 days as a result of various analysts’ ratings changes.
Brokers have set a 12 month consensus price objective of $4.67 for the company and are predicting that the company will post ($0.12) earnings per share for the current quarter, according to Zacks. Zacks has also given Aerpio Pharmaceuticals an industry rank of 48 out of 256 based on the ratings given to its competitors.
Separately, HC Wainwright restated a “neutral” rating on shares of Aerpio Pharmaceuticals in a report on Wednesday, June 12th.
Aerpio Pharmaceuticals (NYSE:ARPO) last announced its quarterly earnings data on Thursday, May 9th. The company reported ($0.21) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.20) by ($0.01).
About Aerpio Pharmaceuticals
Aerpio Pharmaceuticals, Inc, a biopharmaceutical company, focuses on developing and commercializing treatments for ocular diseases. The company's lead product candidate is AKB-9778, a small molecule activator of the Tie2 pathway, which completed the Phase 2a clinical trial for the treatment of diabetic retinopathy.
See Also: Candlestick
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aerpio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerpio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.